| Literature DB >> 29208974 |
Derek Muir1, Denina Simmons2, Xiaowa Wang2, Tom Peart2, Maria Villella2, Jason Miller2, Jim Sherry2.
Abstract
The bioaccumulation of a broad range of pharmaceuticals and personal care product chemicals (PPCPs) was studied in Cootes Paradise Marsh (CPM), an urban wetland that receives tertiary treated municipal waste waters as well as urban storm runoff. We measured PPCPs in caged and wild goldfish, as well as wild carp, and compared observed bioaccumulation factors (BAFP) using concentrations in surface waters and fish blood plasma, with modeled BAFs. Thirty-two PPCPs were detected in water from the central CPM site (CPM3) while 64 PPCPs were found at higher concentrations at a site immediately downstream of the effluent outflow (CPM1). Following a 3-week deployment, 15 PPCPs were detected in the plasma of caged goldfish at CPM1, and 14 at CPM3, compared to only 3 in goldfish caged at a reference site. The highest BAFP in goldfish were for the antidepressant Σfluoxetine averaging 386 L/kg in caged and 906 L/kg in wild goldfish, respectively. In carp, ΣDiazepam (diazepam and oxazepam) had the highest BAFP (927 L/kg). This study identified a broader range of PPCPs in fish and surface waters than previously reported. However, modeled BAFs did not show good agreement with observed whole body or plasma BAFs, demonstrating that more work is needed to better explain bioaccumulation of PPCPs.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29208974 PMCID: PMC5717258 DOI: 10.1038/s41598-017-15462-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PPCPs detected in surface waters of Cootes Paradise Marsh. Inflowing WWTP influenced waters of the Desjardins Canal outflow CPM1, middle and distant sites CPM2, CPM3, and in Jordan Harbour (JH), a reference site. Results for CPM1 are averages of 4 sampling times (ranges shown as vertical bars). CPM2 and CPM3 are single samples while JH is an average of two samples. The horizontal axis labels are for 62 analytes (including 7 with combined parent and transformation products) detected in water at CPM1 (full tabulated list in SI Table S2).
Figure 2PPCPs detected in plasma of caged goldfish at the same sampling locations in Cootes Paradise Marsh (July 2014). Bars represent concentrations in a single pooled sample from 25 fish. Cage deployment sites are the same as those for water. See SI Table S1 for a tabulated list of the analytes on the horizontal axis.
Figure 3Mean concentrations and range of PPCPs detected in plasma of wild goldfish and wild carp collected in Cootes Paradise Marsh and the reference site (JH). Error bars represent standard deviations. See SI Table S1 for a tabulated list of the analytes on the horizontal axis and SI Table S4 and S5 for concentrations in individual sample pools.
Figure 4Bioaccumulation factors (L/kg) for PPCPs goldfish and carp in Cootes Paradise (conc’n in fish plasma ÷ conc’n in water) and in carp from Jordan Harbour (JH). Error bars represent standard deviation based on concentrations in fish. Substances labelled with “<” had BAFP that could not be calculated due to non-detect concentrations in water or fish plasma.
Range of concentrations of PPCPs detected in blood plasma of goldfish and carp along with predicted blood-water partitioning (PBW) and plasma concentrations (FPC).
| caged goldfish plasma | wild goldfish | Cootes carp | log D (pH 7.7) | Predicted plasma bioaccumulation parameters | Therapeuticc “normal” ng/mL | toxic dosed ng/mL | Cmax ng/mLe | |||
|---|---|---|---|---|---|---|---|---|---|---|
| ng/gb | ng/g | ng/g | PBW | FPC ng/mL | Schulz | Schulz | Berninger & Brooks[ | |||
| Erythromycin-H2O | Antibiotic | 0.23–0.66 | 0.22–0.5 | 0.35–0.79 | 2.93 | 22.9 | 0.150 | 500–6000 | 12000–15000 | |
| Sulfamethazine | Antibiotic | 0.06–0.17 | — | — | 0.19 | 1.06 | 0.0003 | |||
| Flumequine | Antibiotic | 0.16–1.37 | 0.15–1.1 | 0.16–1.23 | −0.40 | 0.92 | 0.002 | |||
| Triclocarban | Antimicrobial | — | — | 0.32–3.35 | 4.90 | 605 | 0.909 | |||
| Valsartan | Antihypertensive | — | — | 0.42–1.23 | −0.49 | 0.91 | 0.003 | ~800–6000 | ||
| Diphenhydramine | Anticholinergic | 0.06–0.25 | 0.06–0.23 | — | 2.17 | 7.02 | 0.009 | 50–100 | 1000–2000 | 50 |
| Benztropine | Anticholinergic | — | — | 0.05–0.41 | 1.48 | 2.76 | 0.001 | 10–180 | 50 | |
| Iopamidol | Contrast agent | 7.85–8.35 | 8.2–20.9 | — | −2.42 | 0.84 | 0.178 | |||
| ΣCaffeine | Stimulant | 1.47–1.57 | 1.46–3.38 | 1.58–5.05 | −0.07 | 0.98 | 0.097 | 4000–10000 | 15000–20000 | |
| DEET | Repellent | 0.23–0.58 | 0.31–0.42 | 0.19–1.15 | 2.18 | 7.08 | 0.369 | |||
| Gemfibrozil | Lipid regulator | 0.15–0.86 | 0.15–0.15 | 0.16–0.83 | 1.83 | 4.30 | 0.003 | ~25000 | ||
| ΣIbuprofen | NSAID | — | — | 4.67–4.67 | 0.68 | 1.34 | 0.054 | 15000–30000 | 200000 | |
| ΣDiazepam | Antidepressant | 0.41–1.34 | 0.39–0.81 | 1.18–33.7 | 2.82 | 19.2 | 0.207 | 100–2000 | 3000–5000 | |
| Venlafaxine | Antidepressant | 0.04–0.26 | 0.04–0.17 | 0.04–0.27 | 1.70 | 3.62 | 0.030 | 100–400 | 1000–1500 | |
| Citalopram | Antidepressant | 0.04–0.13 | 0.04–0.16 | — | 3.28 | 86.8 | 0.194 | 50–110 | 220 | |
| ΣFluoxetine | Antidepressant | 0.31–1.5 | 0.32–1.18 | 0.18–0.34 | 1.42 | 2.58 | 0.002 | 120–500 | 1000 | 330 |
| ΣAmitriptyline | Antidepressant | 0.04–0.15 | 0.05–0.07 | 0.02–0.05 | 4.92 | 626 | 0.566 | 50–300 | 500–600 | |
| Sertraline | Antidepressant | 0.04–0.24 | 0.04–0.11 | 0.04–0.13 | 3.51 | 59.5 | 0.021 | 50–250 | 290 | 290 |
| Σantidepressants | 0.89–3.61 | 0.87–2.49 | 1.46–34.5 | |||||||
The range of human therapeutic and toxic doses is presented where availablea.
aNote that results from Schultz et al. and Berninger & Brooks are converted from µg/mL in the original publications to ng/mL, for comparison with the fish plasma data.
bConcentrations are expressed as ng/g plasma as reported by the analytical laboratory but are equivalent to ng/mL assuming a density of 1 g/mL.
cTherapeutic: blood-plasma/serum concentrations (in general, trough at steady state) observed following therapeutically effective doses; no or only minimal side effects (drugs); “normal”: concentrations associated with no or only minimal toxic effects (other xenobiotics)[56].
dToxic: blood-plasma/serum concentrations which produce toxicity/clinically relevant side effects/symptoms.
eCmax = human therapeutic dose.